Although the resistance to the cytotoxic response of certain DNA damaging agents has been well characterized in cells deficient in mismatch repair, little is known about how such resistance affects mutagenesis. Using human cancer cell lines defective in mismatch repair (MMR) and complementary cell lines in which the MMR defects were corrected by chromosome transfer, we present the cytotoxic effect and the mutagenic response at the hypoxanthine-guanine phosphoribosyl transferase (HPRT) locus following exposure to the chemotherapeutic agent, 6-thioguanine (6-TG). Upon exposure to 6-TG, there was a differential cytotoxic response. The MMR-deficient cells were resistant to 6-TG exposure up to 5 µM, whereas the MMR-proficient cell lines were significantly more sensitive at the same levels of exposure. Furthermore, the mutagenic response at HPRT induced by 6-TG was substantially increased in the MMRdeficient lines relative to the MMR-proficient cell lines. These findings support the notion that cytotoxicity to 6-TG is mediated through functional MMR and that resistance to the cytotoxic effects of 6-TG is directly associated with an increase in induced mutations in MMR-defective cells. These data suggest that the use of 6-TG as a chemotherapeutic agent may result in the selection of MMR-defective cells, thereby predisposing the patient to an increased risk for developing secondary tumors.
Introduction
Mismatch repair (MMR) in humans helps provide genomic stability by removing replication errors from DNA in a strandspecific manner (1) (2) (3) (4) (5) . Loss of MMR results in a substantial elevation in mutation rates at endogenous loci and in microsatellite sequences (6) (7) (8) (9) (10) (11) (12) . The finding of mutations in specific MMR genes in families predisposed to colorectal cancer (13) (14) (15) has lead to the hypothesis that the loss of MMR results in genomic instability and increased tumor risk observed in Abbreviations: FBS, fetal bovine serum; HAT, DF medium ϩ 100 µM hypoxanthine, 0.4 µM aminopterin and 16 µM thymidine; HNPCC, hereditary non-polyposis colon cancer; HPRT, hypoxanthine-guanine phosphoribosyl transferase; MMR, mismatch repair; MNNG, N-methyl-NЈ-nitro-N-nitrosoguanidine; O 6 -meG, O 6 -methylguanine; 6-TG, 6-thioguanine; DF Medium, Dulbecco's modified Eagle's medium/Ham's F-12 (1:1) ϩ 10% dialyzed fetal bovine serum.
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patients within these families. Thus, a high rate of genomic instability, or a mutator phenotype, may serve as a critical early step in carcinogenesis (16) . The specific genes implicated in the human MMR pathway include homologues of the bacterial MMR proteins MutS and MutL (1) (2) (3) (4) (5) : hMSH2, hMSH3, hMSH6 (GTBP), hMLH1 and hPMS2. The protein products of these genes appear to function as heterodimers in MMR, such as the mismatch recognition heterodimers, hMSH2/hMSH6, designated hMutSα (17) (18) (19) , and hMSH2/ hMSH3, designated hMutSβ (20) , and the repair complex heterodimer, hMLH1/hPMS2, designated hMutLα (21) . Recent studies have suggested specific binding and repair of DNA mismatch or loop substrates by the hMSH2/hMSH6 and hMSH2/hMSH3 heterodimers (11, 17, 20, 22, 23) , where singlebase mismatch correction is associated with the hMSH2/ hMSH6 heterodimer and repair of 2-to 4-base loops is associated with the hMSH2/hMSH3 heterodimer. However, a functional overlap in mismatch recognition, rather than specific recognition capabilities, appears to be present in the human pathway (24) , as first suggested by overlapping in vitro binding specificity for the individual heterodimers (20, 23) .
Recent studies have shown that cell lines defective in MMR are resistant to DNA-damaging agents such as alkylating agents and some chemotherapeutic agents (9, (25) (26) (27) (28) . The current model for such MMR-mediated cytotoxicity proposes that active repair of DNA damage-induced mismatches produces the appropriate cell-cycle signals necessary for cytotoxicity (25, 29, 30) . One study has also indicated that cells deficient in MMR have a lower incidence of chromosomal aberrations following alkylation damage as compared with MMR-proficient cells (29) . These data suggest that single-strand breaks may be produced by MMR, and that these strand breaks signal cell-cycle arrest and induce apoptosis or other forms of cell death (25, 29, 30) . Lack of repair therefore allows MMRdefective cells to escape cytotoxic insults induced by DNA damage by failing to generate the appropriate cell-cycle signals that normally inhibit cell growth. Indeed, studies have demonstrated that a cell line defective in the MMR gene, hMLH1, lacks a G 2 cell-cycle checkpoint following exposure to Nmethyl-NЈ-nitro-N-nitrosoguanidine (MNNG) or to 6-thioguanine (6-TG) (30, 31) . Complementing the hMLH1 defect by transferring a normal human chromosome 3 to this cell line restores the G 2 arrest following exposure to MNNG or 6-TG, which illustrates the involvement of MMR.
Resistance to alkylating agents in MMR-deficient cells appears to be related to the ability of an alkylating agent to produce adducts at the O 6 position of guanine (9, 25, 26, 32, 33) . For example, O 6 -methylguanine (O 6 -meG) adducts are among the major adducts formed by MNNG and N-methyl-N-nitrosourea (MNU) (reviewed in 34) , and resistance to these alkylating agents is well established in MMR-defective cells (9, 25, 26, 32, 33) . O 6 -meG can potentially miscode during replication, and whereas kinetic analyses have shown that misinsertion of thymine does not occur as frequently as insertion of the normal coding base cytosine, the resulting O 6 -meG:T mismatch yields a 'normal' Watson-Crick configuration and is rapidly extended by the replicative polymerase (36) . Thus, following exposure to MNNG or MNU, O 6 -meG may yield a high frequency of O 6 -meG:T mismatches. The lack of recognition and repair of induced O 6 -meG:T mismatches in MMRdeficient cells may be responsible for the observed resistance in these cells. Furthermore, the human mismatch recognition complex, hMutSα (hMSH2/hMSH6), has been shown to bind to O 6 -meG:T mismatches, demonstrating the recognition of this mismatch by MMR proteins (37) .
Tolerance to alkylation damage has also been associated with a cross-resistance to the purine analog 6-thioguanine (6-TG) in several cell lines (26, 38) . This purine analog is commonly used in the treatment of a variety of human cancers such as acute leukemia (reviewed in 40). Additionally, 6-TGinduced cytotoxicity requires functional MMR (30, 39) . The mechanism of 6-TG cytotoxicity begins with the metabolic processing of 6-TG by hypoxanthine-guanine phosphoribosyl transferase (HPRT) to yield 6-thioguanosine monophosphate. Following subsequent phosphorylation, 6-thioguanosine triphosphate can then by incorporated into genomic DNA (reviewed in 40). Incorporation of 6-TG into DNA is essential for the resulting cytotoxicity induced by this agent (41, 42) . Following incorporation into DNA, 6-TG can readily form mismatches with thymine in a similar miscoding manner as O 6 -meG (43) . Recently it was demonstrated that cells deficient in MMR have fewer chromosome aberrations following 6-TG treatment relative to MMR-proficient cells (44) , similar to that observed previously with alkylation damage (29) , which supports a mechanism of 6-TG-induced cytotoxicity analogous to that described above for alkylating agents. Additionally, it has been proposed that 6-TG in DNA is methylated by Sadenosylmethionine to produce S 6 -methylthioguanine (S 6 -meTG), which also readily miscodes with thymine to yield S 6 -meTG:T mismatches (39) . The resulting S 6 -meTG:T mismatch is recognized by hMutSα (hMSH2/hMSH6) (45) , suggesting that recognition and repair of this resulting mismatch may be partially responsible for the 6-TG-induced cytotoxicity.
Although there are proposed mechanism(s) of cellular resistance to certain alkylation agents and to 6-TG in MMR-deficient cells as described above, little is known about how this resistance affects mutagenesis. If resistance to DNA damage arises as a result of the lack of repair of specific mismatches, then resistance may be at the expense of increased mutations within the cell. That is, unrepaired mismatches may result in mutations during the following round of replication. One study has recently demonstrated a hypermutable response at the transgenic lacI reporter in MMR-deficient mice following treatment to MNU (46) , which supports the hypothesis that MMR-mediated alkylation resistance does result in hypermutability. These findings have fundamental implications for our understanding of carcinogenesis: exposure to normally cytotoxic agents will select for resistant cells defective in MMR, and with increasing rates of genomic mutations, the probability of mutating genes central to the process of neoplastic progression also increases. Given the constant insult in colorectal cells by endogenous and exogenous DNA damaging agents (reviewed in 47, 48) , selection of MMR-defective cells along with inducing mutations within these cells may help explain the high rate of colorectal tumors in hereditary non- 
None ϩ ϩ a Gene defect and complementation by chromosome transfer defined previously (see Materials and methods); HHUA ϩ ch5: hMSH3 complemented; HHUA ϩ ch2: hMSH6 complemented; DLD-1 ϩ ch2: hMSH6 complemented; HCT116 ϩ ch3: hMLH1 complemented. b Designates in vitro repair status using cell extracts and defined substrates (11, 24, 35, 50) .
polyposis colon cancer (HNPCC) families, where individuals are heterozygous for MMR gene function.
In this study, we have tested the hypothesis that cellular resistance to 6-TG is caused by the active role of MMR, and that this resistance is associated with induced mutations. 6-TG was used as a model compound because of the specific mismatch induced, namely 6-TG:T. The cytotoxicity and induced mutant frequency at the HPRT locus from 6-TG exposure were determined for several cell lines defective in MMR. In order to implicate MMR as causative in the observed cytotoxic and mutagenic responses, cell lines were used where the MMR-gene defects defined in each parental cell line were complemented by transferring a normal human chromosome containing a wild-type gene to the defective cells. Our findings support the hypothesis that cytotoxicity from 6-TG exposure is mediated through functional MMR, as indicated by resistance to 6-TG treatment in a MMR-deficient cell compared with susceptibility in the complemented MMR-proficient cells. Furthermore, the mutant frequency induced by exposure to low doses of 6-TG is significantly increased in the MMRdeficient lines, relative to the MMR-proficient chromosome transfer derived cell lines.
Materials and methods

Cell lines
The genotypes and phenotypes of the human cancer cell lines and the matched lines derived by chromosome transfer used in this study are presented in Table I . The heterodimers that are implied to function in the different cell lines derived by chromosome transfer are inferred from in vitro studies using cell extracts and defined substrates (11, 24, 35, 50) . The molecular defects in the parental cell lines have been defined previously: the DLD-1 cell line contains mutations in the hMSH6 gene (22) , HCT116 cells are defective in hMLH1 (49) , and the HHUA cell line contains mutations in both the hMSH6 gene and the hMSH3 gene (11) . MMR-proficient cell lines were derived by chromosome transfer as described previously (35) . The DLD-1 cell clone that received chromosome 2 (wild-type hMSH6) was designated DLD-1 ϩ ch2-1 (clone 1) (50), the HCT116 cell clone that received chromosome 3 (wild-type hMLH1) was designated HCT116 ϩ ch3-6 (clone 6) (35) , and the HHUA cell clones that received either chromosome 2 or 5 were designated HHUA ϩ ch2-5 (wild-type hMSH6, clone 5) (24) or HHUA ϩ ch5-10 (wild-type hMSH3, clone 10) (11). All cell lines were maintained in DF medium [Dulbecco's modified Eagle's medium/Ham's F-12 (1:1) ϩ 10% dialyzed fetal bovine serum (FBS) (HyClone)]. All cell lines carrying transferred chromosomes were maintained in G418 medium [DF medium ϩ 400 µg (active)/ml G418 (Gibco BRL, Gaithersburg, MD)].
6-TG cytotoxicity
The cytotoxic response to increasing levels of 6-TG (Sigma) was determined for each cell line. All cell lines were exposed to 6-TG and the colony-forming ability determined. Cells were first plated in DF medium at cloning efficiency density (~500 cells) in 10 cm dishes from batch cultures to ensure the same cell number was plated per dish. Three dishes were plated for each dose of 6-TG (0-5 µM), as well as for an untreated control. Cells were allowed to adhere to dishes for 12-15 h following plating. For exposure to 6-TG, media was removed and replaced with media containing various doses of 6-TG and exposed for 24 h, after which 6-TG was removed and replaced with fresh medium. Cells were allowed to grow for 12-14 days, and colonies visualized by staining with 0.5% crystal violet (Sigma; in 50% methanol). Colonies with ജ50 cells were counted, and percent survival was calculated as the average number of colonies for each dose relative to untreated control plates. Each cytotoxicity determination was then repeated an additional two times, and the average of all three independent experiments obtained.
6-TG-induced mutant frequency
The induced mutagenic response at the HPRT locus to specific doses of 6-TG was determined by a procedure modified from McCormick and Maher (51) . Briefly, cell lines were first cleansed of pre-existing HPRT mutants by culturing in HAT medium [DF medium ϩ 100 µM hypoxanthine, 0.4 µM aminopterin and 16 µM thymidine (HAT) (Sigma)] for a minimum of five passages. Following removal of the HAT medium from cell cultures, cells were plated in three separate 175 cm 2 flasks at a density of 1.5ϫ10 6 cells. Plating at this density allowed for 6-TG exposure at a density of Ͻ10 4 cells per cm 2 . At 24 h after plating, the medium was removed and replaced with 6-TGcontaining medium for treatment. For each experiment, 1 and 3 µM doses of 6-TG were used. A third flask used was as a non-treated control. 6-TG was removed from the flasks after 24 h and the media was replaced with fresh DF medium. The cells were allowed an expression period of 8-10 days following exposure, during which population doublings were monitored. To maintain cells in logarithmic growth, cultures were split at 80% confluence and replated at a density of 1.5ϫ10 6 cells. Following the expression period, the HPRT mutant frequency was then determined for 5ϫ10 5 cells in 40 µM 6-TG. The mutant frequencies obtained for the untreated control cultures were then subtracted from the mutant frequency obtained in the exposed cultures to yield an induced mutant frequency (observed mutant frequency in treatedobserved mutant frequency in untreated). The induced mutant frequency determinations were then performed two additional times, and the average of all three independent experiments reported.
Statistical analysis
Statistical comparisons relating to cytotoxicity (percent survival) and induced mutant frequency were performed using either a Fisher's least significant difference (LSD) test or an unpaired t-test assuming equal variance (52) . Since data involving the HHUA cell lines consisted of three independent variables, the LSD test was used. If the LSD test indicated a significant difference among all three groups, differences between individual groups were determined by ANOVA. For data involving either the DLD-1 or HCT116 cell lines, the unpaired t-test was performed comparing data from only two groups.
Results
6-TG cytotoxicity
The cytotoxic effects of increasing doses up to 5 µM 6-TG were determined for all cell lines. The 6-TG cytotoxicity curves obtained for all cell lines are presented in Figure 1 . These cytotoxicity curves represent percentage survival at increasing exposures to 6-TG relative to a non-exposed control. The parental HHUA cell line was relatively resistant to 6-TG exposure at the high dose of 5 µM (85% survival) ( Figure 1A) . The HHUA ϩ ch2 cell line, which complements the hMSH6 defect in HHUA cells, was much more sensitive to 6-TG (28% survival at 5 µM 6-TG). The observed cytotoxic response in HHUA ϩ ch2 was significantly different relative to the HHUA parental line for all doses examined (P Ͻ 0.05 at 0.5 µM 6-TG; P Ͻ 0.01 for all remaining doses). The cytotoxic response of the HHUA ϩ ch5 cell line, however, was similar to the response observed for HHUA cells. HHUA ϩ ch5 complements the hMSH3 defect present in HHUA cells. In HHUA ϩ ch5 cells, the response to 6-TG was only different from HHUA cells at the highest dose of 5 µM (P Ͻ 0.05; 73% survival). In contrast, the cytotoxic response in HHUA ϩ ch5 cells was significantly different from HHUA ϩ ch2 at all doses Ͼ1.0 µM (P Ͻ 0.01).
The parental DLD-1 cell line and the DLD-1 ϩ ch2 cell line, in which the defective hMSH6 gene in the parental DLD-1 cells is complemented, showed a significantly different cytotoxic response to 6-TG ( Figure 1B) . That is, the parental DLD-1 cell line was resistant to 6-TG up to 5 µM (80% survival), whereas DLD-1 ϩ ch2 cells were significantly more sensitive to all doses Ͼ1.0 µM (P Ͻ 0.01; 22% survival at 5 µM 6-TG). Similarly, the HCT116 cell line ( Figure 1C ) was relatively resistant to 6-TG at all doses (83% survival at 5 µM 6-TG), whereas the HCT116 ϩ ch3 cell line, in which the hMLH1 defect in HCT116 cells is complemented, was much more sensitive to the cytotoxic effects of 6-TG (20% survival at 5 µM 6-TG). This represented a significant difference in cytotoxicity between the HCT116 and the HCT116 ϩ ch3 cell lines at all doses (P Ͻ 0.05 for the 0.5-1.5 µM doses; P Ͻ 0.01 for the 3.0 and 5.0 µM doses).
6-TG-induced mutant frequency
Following the determination of the cytotoxic effects caused by exposure to 6-TG, the induced mutant frequency at the HPRT locus was determined for all cell lines. This procedure utilized cell populations that had been cleansed of HPRT mutants by culturing in HAT medium. Culturing cells in HAT medium selects for a functional, wild-type HPRT protein, which not only ensured that 6-TG would be incorporated into DNA during treatment but also that it eliminated virtually all pre-existing HPRT mutants. HAT cleansing therefore minimized the possibility of 'selecting' for a population of preexisting HPRT mutants, which may have ultimately biased the observed mutant frequencies, since HPRT mutants that do not incorporate 6-TG into their DNA may have a growth advantage over wild-type HPRT cells that do incorporate 6-TG into their DNA.
Two exposure doses of 6-TG were chosen to allow for comparisons of cytotoxicity and induced mutagenesis between cell lines. A low dose of 6-TG (1 µM) resulted in modest differences in cell survival, and a higher dose of 6-TG (3 µM) produced a significantly greater cytotoxic response in the MMR-proficient cell lines as compared with the MMR-deficient parental lines. Following a 24 h exposure to 6-TG, the cell population was allowed a sufficient period of time for phenotypic expression (8-10 days). Population doubling was carefully monitored in all cultures during the phenotypic expression period. In these studies, control (untreated) cells underwent approximately the same number of population doublings as did treated cells during the phenotypic expression period (data not shown). This suggests that the levels of 6-TG exposure used in these studies (1 and 3 µM) had little effect on the growth rate of wild-type HPRT cells in the treated cultures, or conversely, there did not appear to be a growth advantage for any pre-existing 6-TG-resistant clones that may have escaped HAT cleansing. Thus, differences in the induced mutant frequencies cannot be attributed to 'selection' of preexisting 6-TG-resistant clones.
Following the expression period, the mutant frequency was determined for all cultures. By subtracting the mutant frequency determined in a parallel control (non-exposed) cell culture, the mutant frequency induced by either dose was determined. The induced mutant frequencies were the frequencies determined for treated cells above the values given for the controls, and provide a convenient measure to compare the induced response in different cell lines. The induced mutant frequencies obtained for both doses of 6-TG in all cell lines are presented in Table II (along with cytotoxicity data for each dose of 6-TG) and in Figure 2 .
In the HHUA cell line, which is defective in the MMR genes hMSH3 and hMSH6, there was a substantial increase in mutant frequency for both doses of 6-TG (Figure 2 and Table II ). For HHUA ϩ ch2 (hMSH6-complemented), however, the response was minimal for both doses. This correlated with a 92 and 95% reduction in the induced mutant frequency 1934 observed in HHUA for 1 and 3 µM 6-TG, respectively (Table II) . The induced mutant frequencies between HHUA and HHUA ϩ ch2 were significantly different at P Ͻ 0.01 for both doses of 6-TG. For HHUA ϩ ch5 (hMSH3-complemented), the mutational response to 6-TG was intermediate to the response observed in the HHUA and HHUA ϩ ch2 cell lines. Relative to the HHUA cell line, there was a 53 and 61% reduction in the induced mutant frequency at 1 and 3 µM 6-TG, respectively. The induced mutant frequencies observed in HHUA ϩ ch5 were significantly reduced from those observed in HHUA (P Ͻ 0.05 and P Ͻ 0.01 for 1 and 3 µM 6-TG, respectively).
The induced mutant frequencies at the HPRT locus determined for the DLD-1 cell lines are presented in Figure 2 and Table II . The mutational response to 6-TG in DLD-1 ϩ ch2 (hMSH6-complemented) was significantly reduced relative to the hMSH6-defective parental line for both doses of 6-TG (P Ͻ 0.01). The induced mutant frequency in DLD-1 ϩ ch2 correlates to a 89 and 94% reduction in the mutagenic response observed in DLD-1 for 1 and 3 µM 6-TG, respectively. A similar response was also observed in the HCT116 cell lines, where the parental, hMLH1-defective HCT116 line showed a substantial increase in the induced mutant frequency relative to the hMLH1-complemented HCT116 ϩ ch3 cell line. The induced mutant frequencies for the HCT116 ϩ ch3 cell line were reduced by 87 and 93% for 1 and 3 µM 6-TG, respectively, as compared with the induced mutant frequencies observed in HCT116 cells. The mutational responses between HCT116 and HCT116 ϩ ch3 were significantly different at P Ͻ 0.01 for both doses of 6-TG.
Discussion
Here we examined the cytotoxic and mutagenic response to 6-TG exposure in human cell lines with defined defects in specific MMR genes. Moreover, the defects in these lines were complemented by chromosome transfer, which restores in vitro mismatch repair activity to the cells (Table I) . Therefore, differences in the cytotoxic and mutagenic response to 6-TG between the parental cell lines and the defect-complemented chromosome transfer lines can be attributed to MMR status. Following incorporation into DNA, 6-TG can selectively miscode with thymine, resulting in a 6-TG:T mismatch (43). Alternatively, 6-TG in DNA can be methylated to yield S 6 -methylthioguanine (S 6 -meTG), which also readily miscodes with thymine to yield S 6 -meTG:T mismatches (39) . Either way, 6-TG selectively produces a specific mismatch with thymine. For the sake of simplicity, both potential mispairs (6-TG:T and S 6 -meTG:T) will be collectively referred to as 6-TG:T. Thus, the repair of this specific altered base pair by proteins involved in human MMR can be investigated.
hMSH6/hMSH3-defective cells
The HHUA cell line is defective in the MMR genes hMSH6 and hMSH3 (11) , and therefore, potentially lacks all hMSH2-dependent mismatch recognition. When exposed to 6-TG at high doses, HHUA cells exhibited a high level of resistance ( Figure 1A) , supporting previous findings that MMR is necessary for 6-TG cytotoxicity (30, 39) . Transferring a functional hMSH6 gene to HHUA cells by chromosome transfer returns sensitivity to the cytotoxicity induced by 6-TG ( Figure 1A ). This implicates MMR in mediating the cytotoxic actions of 6-TG, and more specifically, suggests that recognition of the resulting 6-TG:T mismatches requires a functional hMSH2/ 6-Thioguanine-induced mutations in mismatch repair-deficient cells a Induced mutant frequency at the HPRT locus (untreated control mutant frequencies subtracted from 6-TG mutant frequencies). hMSH6 heterodimer. In considering the mutagenic response to 6-TG in the HHUA and HHUA ϩ ch2 cell lines, there is a significant difference in the induced mutant frequency at the HPRT locus at both doses (Table II) . With 3 µM 6-TG, there is a 95% reduction in the induced mutant frequency for the HHUA ϩ ch2 cell line relative to the HHUA line. These data suggest that restoration of a functional hMSH6 gene reduces 1935 the mutagenic effects and increases the cytotoxic effects of 6-TG exposure in HHUA ϩ ch2 cells as compared with the HHUA parental line. These findings implicate a functional hMSH2/hMSH6 heterodimer in the recognition and repair of 6-TG:T mismatches. Transferring a normal human chromosome 5, which complements the hMSH3 defect in HHUA cells, produces a more complicated cellular response to 6-TG. Only at the highest dose examined (5 µM) is there significant 6-TG cytotoxicity observed in HHUA ϩ ch5 cells relative to HHUA ( Figure 1A ). These data imply that the hMSH2/hMSH3 heterodimer does not play a significant role in the cytotoxicity induced by 6-TG:T mismatches. On the other hand, there is a reduction in the induced mutant frequency in HHUA ϩ ch5 relative to HHUA (Table II) , which suggests that the hMSH2/hMSH3 heterodimer does function in the repair of 6-TG:T mismatches. The repair of 6-TG:T mismatches in HHUAϩch5 is consistent with the observation that the hMSH2/hMSH3 heterodimer can play a role in the repair of single-base mismatches (24) .
The subtle cytotoxic differences to 6-TG exposure in HHUA ϩ ch5 cells relative to HHUA cells, compared with the significant reduction in the mutagenic response to 6-TG exposure in HHUA ϩ ch5 relative to HHUA, may involve MMRdependent cell-cycle regulation (30, 31) . That is, one possible explanation of these data is that a signal transduction pathway that mediates cell-cycle control and ultimately cytotoxicity is produced through hMSH2/hMSH6 (hMutSα) mismatch binding, and not by hMSH2/hMSH3 (hMutSβ) mismatch binding. Thus, the cells are more resistant to 6-TG because of the lack of cell-cycle arrest, whereas repair of 6-TG:T mismatches by hMSH2/hMSH3 may still occur to significantly reduce the mutagenic effects of 6-TG. Alternatively, since the current model for MMR-mediated cytotoxicity involves the generation of single-strand breaks by active MMR (see Introduction), perhaps the intermediate or reduced levels of repair activity of 6-TG:T mismatches in HHUA ϩ ch5 cells is insufficient to produce enough single-strand breaks that would yield a more substantial cytotoxic response.
hMSH6-defective cells
The DLD-1 cell line is defective in the MMR gene hMSH6 (22) , and therefore, defective in the hMSH2/hMSH6-mediated MMR. This cell line is resistant to doses of 6-TG up to 5 µM ( Figure 1B) , and exhibits a significantly elevated induced mutant frequency at the HPRT locus when exposed to 6-TG (Table II) . Restoring a functional hMSH6 gene to DLD-1 cells restores both sensitivity to the cytotoxicity induced by 6-TG ( Figure 1B ) and reduces the induced mutant frequency by 94% following exposure to 3 µM 6-TG. At the equivalent dose, the 6-TG cytotoxicity is 86 and 54% for DLD-1 and DLD-1 ϩ ch2, respectively. These data further support a role for the hMSH2/hMSH6 (hMutSα) heterodimer in mediating the cytotoxic effects of 6-TG and the associated reduction of the 6-TGinduced mutant frequency.
hMLH1-defective cells HCT116 cells are defective in the MMR gene hMLH1 (49) , and have been shown previously to be resistant to 6-TG (30) . The hMLH1-gene product is a subunit in the repair complex heterodimer hMLH1/hPMS2 (hMutLα), that functions in association with either the hMSH2/hMSH6 or hMSH2/hMSH3 heterodimers. Following exposure to 3 µM 6-TG, HCT116 cells exhibit a significantly elevated induced mutant frequency at HPRT (Table II) . Transfer of a normal human chromosome 3, and thus, a wild-type hMLH1 gene, causes HCT116 ϩ ch3 cells to become substantially more sensitive to the cytotoxic effects of 6-TG ( Figure 1C ) (30) . The mutational response to 3 µM 6-TG observed in HCT116 ϩ ch3 cells is also reduced by 93% (Table II) . These findings further implicate repair complex formation, mediated by the hMLH1/hPMS2 heterodimer, in 6-TG cytotoxicity and in the repair of 6-TG:T mismatches.
In summary, we have demonstrated that both resistance to the cytotoxic effects and the induced mutagenic effects of 6-TG exposure are mediated by MMR. The cellular responses to 6-TG were determined in MMR-deficient cells with specific MMR-gene defects and in cell lines carrying wild-type MMR genes following transfer of a specific chromosome that results in the complementation of MMR defects in the parental cells. The relative cytotoxicity and induced mutant frequencies in these matched cell lines provide strong evidence for the involvement of specific genes in the repair of 6-TG:T mismatches. Therefore, the loss of MMR can be directly implicated in the resistance to 6-TG while resulting in a substantial increase in mutagenesis.
The use of the purine analog 6-TG in this study has allowed for a description of the cellular response to a specific singlebase mispair. Following incorporation into DNA, 6-TG can readily miscode with thymine. This 6-TG:T mismatch is similar structurally to the O 6 -meG:T mismatch that may result following alkylation at the O 6 position of guanine. Moreover, there appears to be a similar MMR response to both 6-TG:T and O 6 -meG:T mismatches. The cytotoxic and mutagenic responses presented here for 6-TG are consistent with those obtained with MNU (9, 25, 32, 46) , which produces a high yield of O 6 -meG (34) , supporting the use of 6-TG as a model compound for such damage. The loss of MMR has been observed in many human cancers (1-3), suggesting a mechanism of carcinogenesis where cells defective in MMR are selected from MMR-proficient cells following DNA damage. With an increase in induced genomic mutations associated with the resistance phenotype, the probability of mutating essential growth control genes is increased, thereby promoting tumorigenesis. Considering the widespread use of 6-TG and DNA alkylating agents as chemotherapeutic agents, treatment with such agents may result in the selection of genetically unstable, MMR-defective cells, thereby increasing the probability of secondary tumors.
